NINDS Mucolipidoses Information Page

Skip secondary menu

Mucolipidoses

Information Page

Publications
Organizations
Clinical Trials
News
Research literature

Disclaimer

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

Print-friendly version

Email this page

Condensed from Mucolipidoses Fact Sheet

Table of Contents (click to jump to sections)
What are Mucolipidoses?
Is there any treatment?
What is the prognosis?
What research is being done?

Organizations
Publicaciones en Español

What are Mucolipidoses?
The mucolipidoses (ML) are a group of inherited metabolic diseases that affect the body’s ability to carry out the normal turnover of various materials within cells. In ML, abnormal amounts of carbohydrates or fatty materials (lipids) accumulate in cells. Because our cells are not able to handle such large amounts of these substances, damage to the cells occurs, causing symptoms that range from mild learning disabilities to severe mental retardation and skeletal deformities.

The group includes four diseases:

Mucolipidosis I (sialidosis)
Mucolipidosis II (inclusion-cell, or I-cell, disease)
Mucolipidosis III (pseudo-Hurler polydystrophy)
Mucolipidosis IV

The MLs are classified as lysosomal storage diseases because they involve increased storage of substances in the lysosomes, which are specialized sac-like components within most cells. Patients with ML are born with a genetic defect in which their bodies either do not produce enough enzymes or, in some instances, produce ineffective forms of enzymes. Without functioning enzymes, lysosomes cannot break down carbohydrates and lipids and transport them to their normal destination. The molecules then accumulate in the cells of various tissues in the body, leading to swelling and damage of organs.

The mucolipidoses occur only when a child inherits two copies of the defective gene, one from each parent. When both parents carry a defective gene, each of their children faces a one in four chance of developing one of the MLs.

Is there any treatment?

No cure for ML currently exists. Therapies are generally geared toward treating symptoms and providing supportive care to the child. For individuals with corneal clouding, surgery to remove the thin layer over the eye has been shown to reduce the cloudiness in the eye. However, this improvement is only temporary. Physical and occupational therapy may help children with motor delays. Children with language delays may benefit from speech therapy. Children at risk for failure to thrive (growth failure) may need nutritional supplements, especially iron and vitamin B12 for patients with ML IV. Respiratory infections should be treated immediately and fully with antibiotics.

What is the prognosis?

Symptoms of ML can be congenital (present at birth) or begin in early childhood or adolescence. Early symptoms can include vision problems and developmental delays. Over time, many children with ML develop poor mental capacities, have difficulty reaching normal developmental milestones, and, in many cases, eventually die of the disease.

What research is being done?

Discovery of the ML genes is enabling NINDS researchers to study the genes' function and will facilitate studies on drugs that may lead to effective treatments. In addition, investigators at grantee institutions are conducting studies on an animal model, Caenorhabditis elegans, which is frequently used to determine the effects of genetic mutations. Other grantees are using the fruit fly model, Drosophila, to study a mutation in the ML IV gene. And one of the research teams involved in the discovery of the ML IV gene is conducting further genetic studies to explore the normal and abnormal functions of the ML IV gene.

Through these and other research efforts, scientists are optimistic that they will one day discover treatments or even prevention strategies for the MLs.

Select this link to view a list of studies currently seeking patients.

Organizations

Mucolipidosis IV (ML4) Foundation 719 East 17th Street Brooklyn, NY 11230 ML4www@aol.com http://www.ml4.org Tel: 718-434-5067 Fax: 718-859-7371	National MPS Society, Inc. 4220 NC Highway 55 Suite 140 Durham, NC 27713 info@mpssociety.org http://www.mpssociety.org Tel: 877-MPS-1001 919-806-0101 Fax: 919-806-2055
National Organization for Rare Disorders (NORD) P.O. Box 1968 (55 Kenosia Avenue) Danbury, CT 06813-1968 orphan@rarediseases.org http://www.rarediseases.org Tel: 203-744-0100 Voice Mail 800-999-NORD (6673) Fax: 203-798-2291	National Tay-Sachs and Allied Diseases Association 2001 Beacon Street Suite 204 Brighton, MA 02135 info@ntsad.org http://www.ntsad.org Tel: 617-277-4463 800-90-NTSAD (906-8723) Fax: 617-277-0134
ISMRD-International Advocate For Glycoprotein Storage Diseases P.O. Box 328 Dexter, MI 48130 info@ismrd.org http://www.ismrd.org Tel: 734-449-1190 Fax: 734-449-9038	Genetic Alliance 4301 Connecticut Avenue, N.W. Suite 404 Washington, DC 20008-2369 info@geneticalliance.org http://www.geneticalliance.org Tel: 202-966-5557 800 336-GENE (4363) Fax: 202-966-8553
National Society of Genetic Counselors 401 N. Michigan Avenue Chicago, IL 60611 nsgc@nsgc.org http://www.nsgc.org Tel: 312-321-6834 Fax: 312-673-6972

Publicaciones en Español

Las Mucolipidosis

Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892

NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.

Return to top

Last updated September 09, 2008